About the Company

Galmed Pharmaceuticals (NasdaqCM: GLMD) is a clinical stage biopharmaceutical company developing treatments for diseases of the liver. The Company’s lead product candidate is aramchol, a synthetic fatty acid/bile acid conjugate for the treatment of nonalcoholic steatohepatitis (NASH). Galmed has released positive Phase IIa results for this program and is planning to initiate a 240 patient Phase IIb with aramchol in the second half of 2014.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research